28 Results

People

  1. Zelenetz
    Zelenetz
  2. Palomba
    Palomba
  3. Brentjens
    Brentjens
  4. Dogan
    Dogan
  5. Park
    Park
  6. Geyer
    Geyer
  7. Riviere
    Riviere
  8. Salles
    Salles
  9. Wang
    Wang
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (23)
  2. Center for Hematologic Malignancies (20)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (11)
  5. GSK Faculty (9)
  6. Adult Leukemia (7)
  7. Sloan Kettering Institute Faculty (5)
  8. Hematologic Malignancies Research (4)
  9. Molecular Pharmacology and Chemistry Program Faculty (4)
  10. Department of Pathology and Laboratory Medicine (3)
  1. "chronic lymphocytic-leukemia"
Formats
  1. Journal Article (23)
  2. Book Section (2)
  3. Editorial (2)
  4. Guidelines (1)
Groups
  1. Department of Medicine (23)
  2. Center for Hematologic Malignancies (20)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (11)
  5. GSK Faculty (9)
  6. Adult Leukemia (7)

More Groups

People
  1. Andrew Zelenetz (6)
  2. Maria Palomba (5)
  3. Ahmet Dogan (3)
  4. Jae Park (3)
  5. Renier Brentjens (3)
  6. Anthony Mato (2)

More People

Years
  1. 2024 (2)
  2. 2023 (1)
  3. 2022 (2)
  4. 2020 (2)
  5. 2019 (3)
  6. 2018 (1)

More Years

Publications
  1. Blood (3)
  2. Cell and Gene Therapies (2)
  3. Journal of Clinical Oncology (2)
  4. eJHaem (2)
  5. Blood and Lymphatic Cancer: Targets and Therapy (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. Nature Publishing Group (5)
  2. American Society of Hematology (3)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. Springer International Publishing Ag (2)
  6. Wiley Blackwell (2)

More Publishers

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol
    Journal Article

    Palmisiano, N. D.; Lee, J. W.; Claxton, D. F.; Paietta, E. M.; Alkhateeb, H.; Park, J.; Podoltsev, N. A.; Atallah, E. L.; Schaar, D. G.; Dinner, S. N.; more...
    eJHaem (2024)

    Fulltext@MSK | Save
  • Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
    Journal Article

    Lamanna, N.; Tam, C. S.; Woyach, J. A.; Alencar, A. J.; Palomba, M. L.; Zinzani, P. L.; Flinn, I. W.; Fakhri, B.; Cohen, J. B.; Kontos, A.; more...
    eJHaem (2024)

    Fulltext@MSK | Save
  • Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy
    Editorial

    Luttwak, E.; Smith, M. R.; Zelenetz, A. D.
    Expert Opinion on Pharmacotherapy (2023)

    Fulltext@MSK | Save
  • The international consensus classification of mature lymphoid neoplasms: A report from the Clinical Advisory Committee
    Guidelines

    Campo, E.; Jaffe, E. S.; Cook, J. R.; Quintanilla-Martinez, L.; Swerdlow, S. H.; Anderson, K. C.; Brousset, P.; Cerroni, L.; de Leval, L.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The EHA research roadmap: Malignant lymphoid diseases
    Editorial

    Dreyling, M.; André, M.; Gökbuget, N.; Tilly, H.; Jerkeman, M.; Gribben, J.; Ferreri, A.; Morel, P.; Stilgenbauer, S.; Fox, C.; more...
    HemaSphere (2022)

    Fulltext@MSK | Save
  • The impact of age on survival in CLL patients receiving ibrutinib as initial therapy
    Journal Article

    Ujjani, C.; Mato, A.; Hill, B. T.; Allan, J. N.; Lansigan, F.; Jacobs, R.; Skarbnik, A.; Tuncer, H.; Pagel, J.; Brander, D.; more...
    Blood and Lymphatic Cancer: Targets and Therapy (2020)

    Fulltext@MSK | Save
  • Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy
    Journal Article

    Mato, A. R.; Roeker, L. E.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D.; Shadman, M.; Ujjani, C. S.; Yazdy, M. S.; Perini, G. F.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Chimeric antigen receptor T cells for lymphomas: Methods, data, and challenges
    Book Section

    Batlevi, Y.; Sauter, C. S.
    In Perales, M. A.; Abutalib, S. A.; Bollard, C. (Eds.) Cell and Gene Therapies (2019)

    Fulltext@MSK | Save
  • Chimeric antigen receptor-T cells for leukemias in adults: Methods, data and challenges
    Book Section

    Geyer, M. B.; Park, J. H.; Brentjens, R. J.
    In Perales, M. A.; Abutalib, S. A.; Bollard, C. (Eds.) Cell and Gene Therapies (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save